Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Jean A. Yared, Elizabeth Hutnick, Ashraf Badros, Mehmet H. Kocoglu, Nancy M. Hardy, Forat Lutfi, Søren M. Bentzen, Jonathan Siglin, Aaron P. Rapoport, Firas El Chaer, Carl Shanholtz, Kathleen Ruehle, Vivek Kesari, Noa G. Holtzman, Hao Xie, Haroon Ahmad, Saurabh Dahiya, Ali Bukhari, Natalie Gahres
Publikováno v:
Neuro Oncol
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associat
Autor:
Ali Bukhari, David Gottlieb, Noa G. Holtzman, Forat Lutfi, Jonathan Siglin, Nancy M. Hardy, Pranshu Mohindra, Seung Tae Lee, Santanu Samanta, Aaron P. Rapoport, Dong Kim, Jean Yared, Mehmet Hakan Kocoglu, Moaath Mustafa Ali, Jason K. Molitoris, Saurabh Dahiya, Ankit Kansagra, Jingsheng Yan
Publikováno v:
Transplantation and Cellular Therapy. 27:S195-S196
Introduction:Chimeric antigen receptor T-cell (CAR-T) therapy has become an important treatment modality for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, many of these patients have aggressive disease and require a f
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Forat Lutfi, Nancy M. Hardy, Seung Tae Lee, Jean Yared, Mehmet Hakan Kocoglu, Saurabh Dahiya, Facundo Zafforoni, Jennie Y. Law, Moaath Mustafa Ali, Dong Won Kim, Aaron P. Rapoport, Ali Bukhari, David Gottlieb
Publikováno v:
Blood. 136:3-4
Introduction: Secondary hemophagocytic lymphohistiocytosis (HLH) is an aggressive life-threatening activation of the immune system triggered by an underlying condition. Use of chimeric antigen receptor therapy (CAR-T) to treat relapsed/refractory dif
Autor:
Firas El Chaer, Magali J. Fontaine, Kathleen Ruehle, Saurabh Dahiya, Ying Zou, Noa G. Holtzman, Zeba N. Singh, Srilakshmi Bathini, Ashkan Emadi, Nancy M. Hardy, Rima Koka, Ashraf Badros, Mehmet H. Kocoglu, Emily Wilding, Jean A. Yared, Aaron P. Rapoport
Publikováno v:
American Journal of Hematology. 94
Autor:
Michael D. Jain, Bijal D. Shah, Gabriel S Krivenko, Saurabh Dahiya, Aaron D. Falchook, Timothy J. Robinson, Hien D. Liu, Austin J. Sim, Aleksandr Lazaryan, Julio C. Chavez, Aaron P. Rapoport, Nicholas B Figura, Marco L. Davila, Sungjune Kim, Frederick L. Locke, Farhad Khimani
Publikováno v:
International journal of radiation oncology, biology, physics. 105(5)
PURPOSE: Axicabtagene ciloleucel (axi-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Bridging therapy may be required for lymphoma control during the manufacturing inte
Autor:
Ashraf Badros, Jean A. Yared, Mehmet H. Kocoglu, Jennie Law, Firas El Chaer, Sattva S. Neelapu, Aaron P. Rapoport, Nancy M. Hardy, Seung Tae Lee, Saurabh Dahiya, Pranshu Mohindra, Noa G. Holtzman
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S182-S183
Introduction Treatment options for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) post-chimeric antigen receptor therapy (CAR-T) are limited. Here, we report the successful treatment of R/R DLBCL with programmed cell death 1 (PD1) in
Autor:
Jean A. Yared, Nancy M. Hardy, Gabriela Sanchez-Petitto, Matthew R. Brown, Megan K. Morales, Noa G. Holtzman, Madhurima Koka, Firas El-Chaer, Saurabh Dahiya, Aaron P. Rapoport
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S370
Introduction Toxoplasmosis is a well-known intracellular protozoan parasite with seroprevalence varying geographically. Relatively asymptomatic in healthy individuals, it's reactivation can be a devastating opportunistic infection in HSCT patients wi
Autor:
Kathleen Ruehle, Hong-Bin Fang, Deniz Marangoz, Gorgun Akpek, Can Ilyas, Vinil Akbulut, Bhavana Bhatnagar, Aaron P. Rapoport, Saul Yanovich, Ashraf Z. Badros
Publikováno v:
Annals of Hematology
We retrospectively evaluated the tolerability and efficacy of fractionated total body irradiation (TBI) (1,200 cGy) and melphalan (MEL) (100–110 mg/m2) myeloablative conditioning in 48 patients with nonremission AML (n = 14), ALL (n = 10), NHL (n =
Autor:
Karen Chagin, Edward A. Stadtmauer, Trupti Trivedi, Frank Fang, Gwendolyn Binder-Scholl, Malini Iyengar, Thomas H. Faitg, Elliot Norry, Tom Holdich, Rafael G. Amado, Aaron P. Rapoport
Publikováno v:
Blood. 130:845-845
Background: NY-ESO-1 and LAGE-1a are cancer-testis antigens that are overexpressed in patients with multiple myeloma (MM), and the incidence of these antigens correlates with tumor proliferation and other high-risk features. Genetically engineered NY